The Role of Protein Loss and Denaturation in Determining Outcomes of Heating, Cryotherapy, and Irreversible Electroporation on Cardiomyocytes

Feng Liu, Priyatanu Roy, Qi Shao, Chunlan Jiang, Jeunghwan Choi, Connie Chung, Dushyant Mehra, John C Bischof

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Atrial fibrillation (AF) currently affects millions of people in the U.S. alone. Focal therapy is an increasingly attractive treatment for AF that avoids the debilitating effects of drugs for disease control. Perhaps the most widely used focal therapy for AF is heat-based radiofrequency (heating), although cryotherapy (cryo) is rapidly replacing it due to a reduction in side effects and positive clinical outcomes. A third focal therapy, irreversible electroporation (IRE), is also being considered in some settings. This study was designed to help guide treatment thresholds and compare mechanism of action across heating, cryo, and IRE. Testing was undertaken on HL-1 cells, a well-established cardiomyocyte cell line, to assess injury thresholds for each treatment method. Cell viability, as assessed by Hoechst and propidium iodide (PI) staining, was found to be minimal after exposure to temperatures ≤ 40 °C (cryo), ≥60 °C (heating), and when field strengths ≥1500 V/cm (IRE) were used. Viability was then correlated to protein denaturation fraction (PDF) as assessed by Fourier transform infrared (FTIR) spectroscopy, and protein loss fraction (PLF) as assessed by bicinchoninic acid (BCA) assay after the three treatments. These protein changes were assessed both in the supernatant and the pellet of cell suspensions post-treatment. We found that dramatic viability loss (≥50%) correlated strongly with ≥12% protein change (PLF, PDF or a combination of the two) in every focal treatment. These studies help in defining both cellular thresholds and protein-based mechanisms of action that can be used to improve focal therapy application for AF.

Original languageEnglish (US)
Article number061007
JournalJournal of Biomechanical Engineering
Volume140
Issue number6
DOIs
StatePublished - Jun 1 2018

Fingerprint

Cryotherapy
Protein Denaturation
Denaturation
Electroporation
Cardiac Myocytes
Heating
Proteins
Atrial Fibrillation
Therapeutics
Cells
Disease control
Electrochemotherapy
Propidium
Fourier transform infrared spectroscopy
Drug and Narcotic Control
Assays
Fourier Transform Infrared Spectroscopy
Cell Survival
Suspensions

PubMed: MeSH publication types

  • Journal Article

Cite this

The Role of Protein Loss and Denaturation in Determining Outcomes of Heating, Cryotherapy, and Irreversible Electroporation on Cardiomyocytes. / Liu, Feng; Roy, Priyatanu; Shao, Qi; Jiang, Chunlan; Choi, Jeunghwan; Chung, Connie; Mehra, Dushyant; Bischof, John C.

In: Journal of Biomechanical Engineering, Vol. 140, No. 6, 061007, 01.06.2018.

Research output: Contribution to journalArticle

@article{125228837da8487d95b965f6916468fe,
title = "The Role of Protein Loss and Denaturation in Determining Outcomes of Heating, Cryotherapy, and Irreversible Electroporation on Cardiomyocytes",
abstract = "Atrial fibrillation (AF) currently affects millions of people in the U.S. alone. Focal therapy is an increasingly attractive treatment for AF that avoids the debilitating effects of drugs for disease control. Perhaps the most widely used focal therapy for AF is heat-based radiofrequency (heating), although cryotherapy (cryo) is rapidly replacing it due to a reduction in side effects and positive clinical outcomes. A third focal therapy, irreversible electroporation (IRE), is also being considered in some settings. This study was designed to help guide treatment thresholds and compare mechanism of action across heating, cryo, and IRE. Testing was undertaken on HL-1 cells, a well-established cardiomyocyte cell line, to assess injury thresholds for each treatment method. Cell viability, as assessed by Hoechst and propidium iodide (PI) staining, was found to be minimal after exposure to temperatures ≤ 40 °C (cryo), ≥60 °C (heating), and when field strengths ≥1500 V/cm (IRE) were used. Viability was then correlated to protein denaturation fraction (PDF) as assessed by Fourier transform infrared (FTIR) spectroscopy, and protein loss fraction (PLF) as assessed by bicinchoninic acid (BCA) assay after the three treatments. These protein changes were assessed both in the supernatant and the pellet of cell suspensions post-treatment. We found that dramatic viability loss (≥50{\%}) correlated strongly with ≥12{\%} protein change (PLF, PDF or a combination of the two) in every focal treatment. These studies help in defining both cellular thresholds and protein-based mechanisms of action that can be used to improve focal therapy application for AF.",
author = "Feng Liu and Priyatanu Roy and Qi Shao and Chunlan Jiang and Jeunghwan Choi and Connie Chung and Dushyant Mehra and Bischof, {John C}",
year = "2018",
month = "6",
day = "1",
doi = "10.1115/1.4039375",
language = "English (US)",
volume = "140",
journal = "Journal of Biomechanical Engineering",
issn = "0148-0731",
publisher = "American Society of Mechanical Engineers(ASME)",
number = "6",

}

TY - JOUR

T1 - The Role of Protein Loss and Denaturation in Determining Outcomes of Heating, Cryotherapy, and Irreversible Electroporation on Cardiomyocytes

AU - Liu, Feng

AU - Roy, Priyatanu

AU - Shao, Qi

AU - Jiang, Chunlan

AU - Choi, Jeunghwan

AU - Chung, Connie

AU - Mehra, Dushyant

AU - Bischof, John C

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Atrial fibrillation (AF) currently affects millions of people in the U.S. alone. Focal therapy is an increasingly attractive treatment for AF that avoids the debilitating effects of drugs for disease control. Perhaps the most widely used focal therapy for AF is heat-based radiofrequency (heating), although cryotherapy (cryo) is rapidly replacing it due to a reduction in side effects and positive clinical outcomes. A third focal therapy, irreversible electroporation (IRE), is also being considered in some settings. This study was designed to help guide treatment thresholds and compare mechanism of action across heating, cryo, and IRE. Testing was undertaken on HL-1 cells, a well-established cardiomyocyte cell line, to assess injury thresholds for each treatment method. Cell viability, as assessed by Hoechst and propidium iodide (PI) staining, was found to be minimal after exposure to temperatures ≤ 40 °C (cryo), ≥60 °C (heating), and when field strengths ≥1500 V/cm (IRE) were used. Viability was then correlated to protein denaturation fraction (PDF) as assessed by Fourier transform infrared (FTIR) spectroscopy, and protein loss fraction (PLF) as assessed by bicinchoninic acid (BCA) assay after the three treatments. These protein changes were assessed both in the supernatant and the pellet of cell suspensions post-treatment. We found that dramatic viability loss (≥50%) correlated strongly with ≥12% protein change (PLF, PDF or a combination of the two) in every focal treatment. These studies help in defining both cellular thresholds and protein-based mechanisms of action that can be used to improve focal therapy application for AF.

AB - Atrial fibrillation (AF) currently affects millions of people in the U.S. alone. Focal therapy is an increasingly attractive treatment for AF that avoids the debilitating effects of drugs for disease control. Perhaps the most widely used focal therapy for AF is heat-based radiofrequency (heating), although cryotherapy (cryo) is rapidly replacing it due to a reduction in side effects and positive clinical outcomes. A third focal therapy, irreversible electroporation (IRE), is also being considered in some settings. This study was designed to help guide treatment thresholds and compare mechanism of action across heating, cryo, and IRE. Testing was undertaken on HL-1 cells, a well-established cardiomyocyte cell line, to assess injury thresholds for each treatment method. Cell viability, as assessed by Hoechst and propidium iodide (PI) staining, was found to be minimal after exposure to temperatures ≤ 40 °C (cryo), ≥60 °C (heating), and when field strengths ≥1500 V/cm (IRE) were used. Viability was then correlated to protein denaturation fraction (PDF) as assessed by Fourier transform infrared (FTIR) spectroscopy, and protein loss fraction (PLF) as assessed by bicinchoninic acid (BCA) assay after the three treatments. These protein changes were assessed both in the supernatant and the pellet of cell suspensions post-treatment. We found that dramatic viability loss (≥50%) correlated strongly with ≥12% protein change (PLF, PDF or a combination of the two) in every focal treatment. These studies help in defining both cellular thresholds and protein-based mechanisms of action that can be used to improve focal therapy application for AF.

UR - http://www.scopus.com/inward/record.url?scp=85045019199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045019199&partnerID=8YFLogxK

U2 - 10.1115/1.4039375

DO - 10.1115/1.4039375

M3 - Article

C2 - 29560492

AN - SCOPUS:85045019199

VL - 140

JO - Journal of Biomechanical Engineering

JF - Journal of Biomechanical Engineering

SN - 0148-0731

IS - 6

M1 - 061007

ER -